ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Mylan Inc. (MYL) Report Updated: Apr 21, 2014 | Print This Page

Get more stock ratings by Louis Navellier

Mylan Inc. (MYL)

Rating: Buy Volatility: Conservative
Total Grade: B Industry: Pharmaceuticals
Competitors: CRME, PCRX, ANIP, BPTH
service keys

Mylan Inc.© quotemedia

Company Profile

Mylan Inc., together with its subsidiaries, engages in the development, manufacture, marketing, licensing, and distribution of generic and branded generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs) worldwide. It operates in two segments, Generics and Specialty. The Generics segment primarily develops, manufactures, sells, and distributes generic or branded generic pharmaceutical products in tablet, capsule, and injectable or transdermal patch forms, as well as API. It also focuses on developing APIs with non-infringing processes to partner with generic manufacturers. This segment serves proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The Specialty segment manufactures and sells branded specialty injectable, nebulized, and transdermal products for life-threatening conditions. Its products include EpiPen Auto-Injector to treat severe allergic reactions; and Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients. This segment serves pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions primarily in the United States. Mylan Inc. also manufactures and sells injectable products in various therapeutic areas for the hospital setting; supplies APIs for the manufacture of antiretroviral (ARV) drugs to treat HIV/AIDS; offers finished dosage form products in the ARV market; and manufactures non-ARV FDF products, as well as focuses on developing, manufacturing, and commercializing dry powder inhaler delivery platform. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan Inc. was founded in 1961 and is based in Canonsburg, Pennsylvania.

Recent News: Mylan Inc.